Gemmer Asset Management’s Denali Therapeutics DNLI Stock Holding History

Gemmer Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6	Closed	–	–	1360
2019 Q3	$0	Buy	+6	New	+$115	﹤0.01%	1404

Other funds holding DNLI

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Gemmer Asset Management's DNLI Position: Q4 2019 in Review

Gemmer Asset Management sold out of Denali Therapeutics (DNLI) in Q4 2019, closing a stake of 6 shares.

Gemmer Asset Management first reported a position in DNLI in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

Gemmer Asset Management reported no remaining Denali Therapeutics position as of Q4 2019 after selling out during the quarter.
Gemmer Asset Management sold 6 Denali Therapeutics shares in Q4 2019.
Gemmer Asset Management first reported a position in Denali Therapeutics in Q3 2019 and held it in 1 quarter.
Gemmer Asset Management's Denali Therapeutics position peaked at $0 in Q3 2019.
108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Gemmer Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.